Skip to main content

Table 3 Changes of the echocardiographic findings in patients with cancer therapeutics-related cardiac dysfunction

From: Left atrial longitudinal strain as a predictor of Cancer therapeutics-related cardiac dysfunction in patients with breast Cancer

  Baseline After
chemotherapy
After
trastuzumab therapy
LVEDVI (mL/m2) 56.8 ± 10.6 57.1 ± 12.3 65.7 ± 12.0
LVESVI (mL/m2) 19.9 ± 5.3 20.4 ± 6.7 35.0 ± 7.7†‡
LVEF (%) 65.0 ± 6.4 64.5 ± 7.4 46.9 ± 4.8†‡
LVGLS (%) −21.0 ± 2.4 − 18.8 ± 2.3* − 15.3 ± 2.6†‡
E (cm/sec) 71.3 ± 10.4 67.5 ± 7.8 84.3 ± 14.7†‡
e’ (cm/sec) 8.8 ± 1.4 7.6 ± 1.3* 7.0 ± 0.8‡
s’ (cm/sec) 7.9 ± 0.9 7.3 ± 1.3 4.5 ± 1.0†‡
E/e’ 8.2 ± 1.0 9.0 ± 1.0 12.0 ± 1.4†‡
LAVI (mL/m2) 25.8 ± 3.8 25.8 ± 3.6 29.1 ± 3.8†‡
PALS (%) 33.1 ± 5.9 28.2 ± 5.5* 23.9 ± 6.0†‡
LA conduit strain (%) 19.2 ± 3.4 14.9 ± 2.9* 12.7 ± 3.2‡
LA booster strain (%) 13.9 ± 2.5 13.3 ± 2.7 11.2 ± 2.8‡
RVSP (mmHg) 29.3 ± 7.1 27.1 ± 7.2 30.2 ± 7.9
  1. LVEDVI left ventricular end-diastolic volume index, LVESVI left ventricular end-systolic volume index, LVEF left ventricular ejection fraction, LVGLS left ventricular global longitudinal strain, E: early diastolic mitral inflow velocity, e’: early diastolic velocity of mitral septal annulus, s’: systolic velocity of mitral septal annulus, LAVI left atrial volume index, PALS peak atrial longitudinal strain, LA left atrium, RVSP right ventricular systolic pressure. *: p < 0.05 between baseline and after chemotherapy, †: p < 0.05 between after chemotherapy and after trastuzumab therapy, ‡: p < 0.05 between baseline and after trastuzumab therapy